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The efficient development and delivery of high-quality therapeutic products necessitates the need for high-
throughput process development (HTPD) tools. In recent years, fed-batch process development timelines have 
been significantly reduced as industry has implemented fully automated mini bioreactor systems such as the 
ambr® 250 HT.  More recently, as continuous processing for biologics has gained traction, driven by novel 
technology and economic pressure to significantly improve monoclonal antibody (mAb) production over the 
standard fed-batch process, more efficient, cost effective, and environmentally sustainable mAb processes are 
expected. Traditionally, perfusion process development work requires a combination of deep-well plates and 
small-scale stirred tank bioreactor (STR), both of which are labor intensive and time consuming. The established 
ambr®250 HT platform has recently been integrated with perfusion capabilities to enable rapid continuous 
perfusion process development (PD). In this work, we present the results from our assessment of the automated 
disposable perfusion bioreactor system for high throughput upstream PD activities, including clone selection and 
process optimization. In addition, several high stress conditions were also examined here to identify optimal 
operation ranges for the current system. The studies conclude that ambr® 250 perfusion reactor is able to 
generate process performance and product quality profiles equivalent to bench-top bioreactors for a high cell 
density perfusion process. 
 
 
 
 
